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Abstract
PP2A is a major tumor suppressor whose inactivation is frequently found in a wide spectrum of human tumors. In particular,
deletion or epigenetic silencing of genes encoding the B55 family of PP2A regulatory subunits is a common feature of breast
cancer cells. A key player in the regulation of PP2A/B55 phosphatase complexes is the cell cycle kinase MASTL (also
known as Greatwall). During cell division, inhibition of PP2A-B55 by MASTL is required to maintain the mitotic state,
whereas inactivation of MASTL and PP2A reactivation is required for mitotic exit. Despite its critical role in cell cycle
progression in multiple organisms, its relevance as a therapeutic target in human cancer and its dependence of PP2A activity
is mostly unknown. Here we show that MASTL overexpression predicts poor survival and shows prognostic value in breast
cancer patients. MASTL knockdown or knockout using RNA interference or CRISPR/Cas9 systems impairs proliferation of
a subset of breast cancer cells. The proliferative function of MASTL in these tumor cells requires its kinase activity and the
presence of PP2A-B55 complexes. By using a new inducible CRISPR/Cas9 system in breast cancer cells, we show that
genetic ablation of MASTL displays a signiﬁcant therapeutic effect in vivo. All together, these data suggest that the PP2A
inhibitory kinase MASTL may have both prognostic and therapeutic value in human breast cancer.
Introduction
Protein phosphatase 2A (PP2A) is the major serine-
threonine phosphatase in mammals. PP2A function as a
multimeric complex containing a catalytic (C), scaffold (A)
and regulatory (B) subunit. Regulatory subunits can belong
to four different subfamilies: B (PR55), B′ (B56 or PR61),
B″ (PR72), and B‴ (PR93/PR110), each one composed of
multiple isoforms. Aberrant expression, mutations and
somatic alterations of the PP2A scaffold and regulatory
subunits have been detected in several types of human
cancer [1, 2]. In particular, deletions in PPP2R2A, the gene
encoding the α isoform of the PP2A regulatory subunit B55,
are amongst the most frequent events in luminal-like breast
cancer and deﬁne a sub-group of aggressive tumors [3, 4].
PPP2R2B, encoding B55β, is frequently inactivated by
methylation in breast tumors [5] and a genetic variant in this
gene associates with altered breast cancer risk and recur-
rence [6], thus suggesting that PP2A-B55 complexes may
play a tumor suppressor role in breast cancer.
During the last years, the cell cycle kinase MASTL (also
known as Greatwall) has emerged as a key player in the
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regulation of PP2A phosphatase during mitosis. MASTL
was originally identiﬁed in Drosophila as a protein required
for DNA condensation and normal progression through
mitosis [7]. MASTL phosphorylates two small proteins,
endosulﬁne (ENSA) and ARPP19, which in their phos-
phorylated form bind and inhibit PP2A-B55 complexes
[8–11]. In vertebrates, PP2A-B55 complexes counteract the
phosphorylation of CDK substrates [12]. The inhibitory
function of MASTL over PP2A is required to maintain the
mitotic state, whereas inhibition of MASTL and reactivation
of PP2A is required for mitotic exit [13–16].
Although the function of MASTL during mitosis has
been deeply characterized in multiple organisms [7], our
understanding of its relevance in human cancer is still
limited. Recent data suggest that MASTL may promote cell
transformation in an ENSA/PP2A-independent manner by
hyperactivating AKT [17]. MASTL is overexpressed in
speciﬁc tumors such as oral squamous cell carcinoma, colon
cancer and neuroblastoma [17–19] and data from knock-
down screens suggest its therapeutic value in thyroid tumor
cells [20, 21]. Mastl is also involved in recovery from DNA
damage [22, 23] and its downregulation may therefore
sensitize cancer cells to radiotherapy [18, 24].
In this work, we focus on the relevance of MASTL
kinase activity in breast cancer, a tumor type in which its
downstream target, PP2A-B55, has been suggested to be
important for cancer progression. Here we show that
MASTL knockdown or knockout using RNA interference or
inducible CRISPR/Cas9 models results in impaired pro-
liferation of some breast cancer cell lines. Sensitive cancer
cells require MASTL kinase activity and expression of the
B55 subunits of PP2A, suggesting the presence of a sub-
group of breast cancer patients that could beneﬁt from
MASTL-directed therapies. Moreover, elevated levels of
MASTL protein correlate with poor disease outcome, and
may have prognostic value in Estrogen Receptor (ER)-
positive breast tumors independently of the Ki67 pro-
liferation marker.
Results
MASTL depletion differentially affects proliferation
in breast cancer cell lines
Given the potential relevance of MASTL-PP2A/B55 pathway
in breast cancer, we ﬁrst analyzed MASTL expression and the
consequences of its depletion in a panel of breast tumor cell
lines, including both hormone-positive/luminal (T47D, MCF-
7, BT-483, EVSA-T, MDA-MB-415) and triple-negative/
basal-like (MDA-MB-231, BT-549, MDA-MB-468,
HCC1143) subtypes. MASTL was differentially expressed in
these cell lines without an obvious correlation with the
estrogen receptor status or the primary oncogenic events
present in these cells (Fig. 1a). We then used different short
hairpin RNAs (shRNAs) to knock down MASTL expression
in these cells. Several sequences including shRNAs #1, 3, 5,
6, 8, and 10 (Supplementary Fig. S1 and Supplementary
Table S1) resulted in a signiﬁcant downregulation of MASTL
expression. However, we realized that some of these
sequences provoked different phenotypes (data not shown)
and decided to test their speciﬁcity in rescue assays in which a
mouse Mastl cDNA (which is insensitive to these shRNAs)
was ectopically expressed. As shown in Supplementary
Fig. S1, only the growth defects caused by shMASTL #8 were
fully rescued by Mastl re-expression, suggesting common off-
target effects after MASTL knockdown by RNAi means. We
therefore decided to use sequence #8 in the rest of the assays.
As an alternative strategy we also decided to use the
CRISPR/Cas9 system to induce genetic disruption of the
MASTL gene. Three different small guide RNAs (sgRNAs)
were tested and sgRNA #2 was selected for further studies
(Supplementary Fig. S1).
Parallel knock down (shRNA #8; shMASTL) and knock
out (sgRNA #2; sgMASTL) assays elicited differential
responses to MASTL depletion after lentiviral infection of a
cell line panel with these sequences. As shown in Fig. 1b,
some cell lines such as MDA-MB-231 or BT-549 were
highly sensitive to MASTL knock down, whereas other cell
lines such as EVSA-T or T47D were largely insensitive,
despite showing similar level of MASTL depletion (Fig. 1c,
d, and Supplementary Fig. S2). A similar trend was
observed in MASTL knock out assays using the CRISPR
reagents, although the differences in sensitivity to MASTL
depletion were not so dramatic in this case (Fig. 1b), per-
haps as a consequence of the complete elimination of
MASTL due to genetic knockout in this technique. Both
knock-down and knock-out of MASTL in the cell line
MCF10-A also impaired proliferation of these non-
transformed mammary epithelial cells (Supplementary
Fig. S2). Interestingly, surviving clones in the resistant cell
lines expressed low levels of MASTL, possibly as a con-
sequence of in-frame indels at the genomic level (Supple-
mentary Fig. S3). These data suggest that complete
elimination of MASTL may be lethal in both sensitive and
relatively insensitive cell lines, but much reduced levels of
this kinase are sufﬁcient to sustain cell proliferation in
resistant cells.
We did not ﬁnd any obvious correlation between the effect
of MASTL depletion and the expression levels of MASTL or
its substrate ENSA among the different tumor cell lines
(Fig. 1a). Both sensitive and insensitive cells displayed a
signiﬁcant reduction in the phosphorylation of ENSA (Sup-
plementary Fig. S2). However, cells with low expression of
B55 subunits, such as EVSA-T or HCC1143, were among
the least affected by MASTL silencing (Fig. 1a, b).
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Inducible MASTL knock out results in cell cycle
defects in a kinase-dependent manner
In order to analyze in more detail the consequences of
MASTL ablation in cancer cells, we generated a conditional
CRISPR/Cas9 system in which MASTL genetic knock out
could be achieved in an inducible manner. We subcloned the
sgRNA #2 sequence in the LC-TRIP vector, which con-
stitutively expresses a green ﬂuorescent protein (GFP), and
conditionally expresses Cas9 and a red ﬂuorescent protein
(dsRed) following treatment with doxycycline (Fig. 2a).
Stable MDA-MB-231 selected clones carrying this construct
showed a clear induction of dsRed after treatment with
doxycycline, which correlated with induction of Cas9
expression (Fig. 2b). We selected one of these clones,
MASTL_sg2#5 (referred to as isgMASTL), in which one of
the MASTL alleles displayed a small deletion even in the
absence of doxycycline, indicating some level of leakiness in
the LC-TRIP vector (Fig. 2c). As previously reported in
mouse cells [16], cells with only one allele of MASTL grew
normally with no differences versus homozygous wild-type
cells (data not shown). Treatment of the isgMASTL clone
with doxycycline resulted in a variety of deletions in the
remaining wild-type allele efﬁciently generating knockout
cells (Fig. 2d), which resulted in the elimination of MASTL
protein (Fig. 2b). No off-target effects were identiﬁed after
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Fig. 1 Effect of MASTL
knockdown and knockout in
breast cancer cell lines. a
Immunoblotting analysis of
MASTL protein abundance in
asynchronous luminal- and
basal-like cancer cell lines.
Protein levels for ENSA/
ARPP19 and the B55 family of
PP2A regulatory subunits were
detected with pan-antibodies
recognizing both ENSA and
ARPP19, and different B55
isoforms, respectively.
Activation of ERK and AKT
oncogenic pathways was
analyzed with the indicated
antibodies. β-actin was used as a
loading control. b Effect of
shRNA-mediated MASTL
knockdown (upper panel) or
CRISPR/Cas9-mediated
knockout (bottom panel) in the
indicated breast cancer cell lines.
Quantiﬁcation of cell growth
based on clonogenic assays is
shown. For each cell line, cell
growth of cells infected with a
scramble-shRNA vector (upper
panel) or an empty vector
expressing only Cas9 (lower
panel) was set as 100%. Bars
indicate means+ SD for at least
three independent experiments. c
Crystal violet staining of a
clonogenic assay in representative
examples of sensitive (MDA-MB-
231) and resistant (EVSA-T) cell
lines. d Western-blot analysis of
MASTL protein levels after
knockdown (shMASTL) or
knockout (sgMASTL) in the two
representative cell lines. Whole-
cell lysates were obtained 5 days
after lentiviral infection. HP
hormone-positive, TNBC triple-
negative breast cancer
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sequencing top-ranking potential off-target genomic sequen-
ces (Supplementary Table S2). As a control for the potential
effects of Cas9 overexpression and/or doxycycline treat-
ments, we selected one clone, Cas9#1 (referred to as iCas9),
which carries the empty vector and therefore also expresses
Cas9 and the ﬂuorescent reporter (dsRed) upon doxycycline
addition (Fig. 2b).
MDA-MB-231 MASTL knock out cells did not show a
defect in mitotic entry (Fig. 3a), but these null cells dis-
played a signiﬁcant increase in the duration of mitosis
(Fig. 3b) accompanied by abnormal chromosome segrega-
tion or lack of segregation resulting in tetraploid cells
(Fig. 3c, d), in agreement with the mitotic defects reported
in other mammalian cells [13, 14, 16, 25]. Genetic ablation
of MASTL was accompanied by a signiﬁcant defect in the
mitotic phosphorylation of its substrate endosulﬁne (ENSA;
Fig. 3e), a small protein that inhibits PP2A-B55 complexes,
an event observed both in sensitive and resistant cells
(Supplementary Fig. S2). MASTL ablation in MDA-MB-
231 cells was also accompanied by a general reduction of
mitotic phospho-CDK substrates known to be depho-
sphorylated in a PP2A-dependent manner. Phosphorylation
of the mitotic marker phospho-histone H3 (pH3S10) did not
change upon MASTL ablation indicating that these defects
were not a consequence of decreased number of mitotic
cells but rather a consequence of a putative PP2A-B55 re-
activation upon MASTL knockout (Fig. 3e). In agreement
with this hypothesis, knock down of B55α and B55δ, the
two ubiquitous members of the B55 family, partially res-
cued the defects observed in MASTL knockout cells
(Fig. 3f-h). Treatment with doxycycline led to an accumu-
lation of 4n and ≥ 4n cells as a consequence of the chro-
mosome segregation failure described above, which was
partially prevented in the presence of reduced levels of
b
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Fig. 2 Inducible genetic
ablation of MASTL using CRISPR/
Cas9 techniques in breast cancer
cells. a Schematic representation
of the sgRNA/cas9- inducible
lentiviral vector used in this
study. b Representative ﬂow
cytometry plots of dsRed
induction in MDA-MB-231 cells
expressing both Cas9 and
sgRNAs against MASTL
(isgMASTL) or control cells
expressing Cas9 alone (iCas9).
Numbers indicate the percentage
of DsRed-positive cells after
4 days treatment with
doxycycline. Immunobloting
analysis of MASTL protein
levels in the absence or presence
of doxycycline (4 days
treatment) in the two MDA-MB-
231 selected clones is shown on
the right panel. Cas9 induction
was monitored with an anti-Flag
antibody. c-d Genomic analysis
of isgMASTL clones. sgRNA
and PAM sequence are
highlighted in yellow and blue
colors, respectively. Red
arrowhead denotes predicted
Cas9 cutting site. Note that this
clone is already heterozygous
for MASTL before treatment due
to a 15 bp deletion that leads to a
frameshift mutation and a
premature stop codon c.
Treatment with doxycycline
results in deletion of MASTL in
both alleles due to 1–43 bp
deletions also causing frameshift
mutations as indicated in panel
d. Representative sequences are
shown
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PP2A-B55 phosphatase (Fig. 3f, g). In agreement with these
results, depletion of B55 subunits rescued the presence of
multipolar mitotic spindles and multinucleated cells in
MASTL-depleted cells. Other mitotic defects induced by
MASTL deletion, such as chromosome mis-alignments in
metaphase or lagging chromosomes and DNA bridges
during anaphase and telophase, were also partially rescued
upon B55 α and δ knock down (Fig. 3h). These data suggest
that the reduced proliferation induced by MASTL ablation
is very likely the consequence of severe mitotic defects,
mostly caused by PP2A-B55 hyper-activation.
We next stably transfected the inducible knock out
MDA-MB-231 model with GFP-tagged wild-type or
kinase-dead (G43S) murine Mastl sequences, which are
insensitive to the sgRNA used in the CRISPR/Casp9 system
(Fig. 4a). As described above, treatment with doxycycline
induced an accumulation of 4n and ≥4n cells as a con-
sequence of the mitotic defects generated upon MASTL
ablation (Fig. 4b). These defects, as well as the reduced cell
growth caused by MASTL knockout were signiﬁcantly
rescued by the wild-type, but not the kinase-dead, Mastl
cDNA (Figs. 4b, c), suggesting that the therapeutic effect
obtained upon MASTL elimination could also be achieved
by inhibiting its kinase activity. All together, these results
conﬁrm the relevance of the ENSA-B55-PP2A pathway in
the therapeutic effects achieved by elimination of MASTL
kinase activity.
MASTL ablation results in defective breast tumor
growth in vivo
To analyze the effect of MASTL ablation on tumor growth
we generated xenografts of the inducible MDA-MB-231
clones. Once these tumors reached 100mm3, mice were
treated with doxycycline-supplemented diet or kept
untreated. We also included a third group of mice that
received a transient treatment during the ﬁrst week and
doxycycline was removed afterwards. As represented in
Figs. 5a, b, mice treated with doxycycline showed a sig-
niﬁcant reduction in tumor size and weight at the endpoint of
the experiment. As an additional control, we also used
MDA-MB-231 clones expressing the inducible Cas9 vector
in the absence of the speciﬁc MASTL sgRNA. Treatment
with doxycycline did not alter growth of these control
tumors suggesting that neither Cas9 nor doxycycline itself
had a signiﬁcant effect in tumor growth (Supplementary
Fig. S4). In the MASTL inducible knock out (isgMASTL)
clone, transient treatment with doxycycline only for 1 week
resulted in an initial reduction in tumor growth but this effect
was lost after elimination of doxycycline (Supplementary
Fig. S4). To discriminate whether this effect was due to
partial efﬁciency by the inducible CRISPR/Cas9 model or to
adaptation to the loss of MASTL, we quantiﬁed the number
of MASTL-positive cells in these tumors. As showed in
Fig. 5c, sustained treatment with doxycycline resulted in a
signiﬁcant induction of Cas9 and decrease in the number of
cells expressing MASTL. However, the percentage of
MASTL-expressing cells was signiﬁcantly higher when
doxycycline treatment was transient, suggesting that these
tumors were repopulated with cells in which MASTL has
not been knocked out (Supplementary Fig. S4). Given that
the activity of the inducible CRISPR/Cas9 model is only
partial, the difference in tumor growth between control and
MASTL-null cells is possibly underestimated in these
assays. Importantly, the reduction in the number of MASTL-
positive cells upon doxycycline treatment correlated with a
reduction in the number of proliferating cells, determined by
Ki67 staining in Cas9-positive cells (Fig. 5d and Supple-
mentary Fig. S4). Moreover, doxycycline-treated tumors
frequently display aberrant nuclear morphologies and bigger
nuclei, suggesting segregation failure due to MASTL abla-
tion, as already observed in cultured cells in vitro (Fig. 5e).
Collectively, the results obtained in these tumor models
suggest that elimination of MASTL activity might be a
valuable therapeutic target in speciﬁc breast tumors.
MASTL overexpression correlates with poor disease
outcome in human breast cancer
Analysis of MASTL expression in human tumors showed
increased levels of the MASTL mRNA in breast cancer
Fig. 3 Cell cycle defects after MASTL knockout are B55-dependent. a-
d Mitosis was monitored by videomicroscopy in isgMASTL cells stably
expressing H2B-GFP in the absence and presence of doxycycline.
Video recording started 48 h after doxycycline administration. Graphs
indicate the percentage of cells entering mitosis a, the duration of
mitosis (DOM) from nuclear envelope breakdown until mitotic exit
based on DNA decondensation and loss of rounded morphology b, and
the classiﬁcation of mitotic aberrations c. Representative time-lapse
images are shown in d. ***, p< 0.001; Student t test. e Western-blot
analysis of MASTL protein levels and phosphorylation and total levels
of its substrate Ensa in the absence and presence of doxycycline (4 days
treatment). Phosphorylation level of CDK substrates is detected with a
pan-antibody against (K/R) pSPX (K/R) motifs. Phosphorylation of
histone H3 is used as a marker of the mitotic state and β-actin is used as
a loading control. Left lanes correspond to asynchronous-growing cells
whereas right lanes represent nocodazole-enriched mitotic cells. Note
that the band corresponding to MASTL is shifted in mitotic cell extracts
due to its hyperphosphorylation state. f Immunoblotting analysis of
B55α (PPP2R2A) and B55δ (PPP2R2D) PP2A subunits upon siRNA
transfection in isgMASTL cells. g siRNA-mediated silencing of
PPP2R2A/D PP2A subunits rescues accumulation of ≥4n cells in
sgMASTL cells. Left panel shows FACs cell cycle proﬁles and the graph
on the right shows the fold induction in the percentage of ≥4n cells upon
doxycycline (Dox) treatment. Bars indicate means+ SD for two inde-
pendent experiments. h Immunoﬂuoresce analysis in isgMASTL cells
transfected with scramble or PPP2R2A/D siRNAs in the presence or
absence of doxycycline (4 days treatment). The graphs show the
quantiﬁcation in percentage (mean+ SD) of the defects detected in
MASTL-depleted cells. At least 40 mitotic cells and 100 interphasic
cells were counted in each condition. Representative pictures of the
indicated phenotypes are shown. Scale bar, 1 µm. Scr scramble
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compared to normal tissue, correlating inversely with
recurrence-free survival in ER-positive breast tumors (Fig. 6a
and Supplementary Fig. S5). To analyze the expression of
this kinase at the protein level in human tissues we ﬁrst
generated a new monoclonal antibody against the human
protein. This antibody identiﬁes a single band in immuno-
blots that corresponds to the expected MASTL size and is
suppressed by speciﬁc short hairpin RNAs against this kinase
(Supplementary Fig. S5). MASTL is mostly nuclear in can-
cer cells as previously described [18] and its expression is
highly variable among tumors (Fig. 6b). We next used this
antibody to detect MASTL in three different cohorts of breast
cancer samples totaling more than 500 patients.
The ﬁrst cohort included 461 patients representing dif-
ferent subtypes of breast cancer from the METABRIC
study. [3] MASTL abundance was signiﬁcantly associated
with higher histological grade (Fig. 6c) and was more evi-
dent in basal-like (Fig. 6d) and ER-negative (Fig. 6e)
tumors. We also detected a positive correlation between
MASTL protein expression and the mRNA levels of Ki67
(Spearman’s rho= 0.18, p= 0.0002) and Aurora A kinase
(Spearman’s rho= 0.21, p= 0.0001), suggesting a possible
link with cell proliferation. Importantly, high levels of
MASTL associated with poor prognosis in this set of
patients (hazard ratio (HR)= 2.3; 95% CI, 1.57–5.02; p=
0.0005), and more robustly in ER-negative (HR= 3.3; 95%
CI, 1.4–10.5; p= 0.01) vs. ER-positive tumors (HR= 1.9;
95% CI, 1.04–4.3; p= 0.04; Fig. 6f).
We also analyzed MASTL expression in two other sets of
breast cancer including hormone receptor-positive (n= 73;
12.5 years of follow-up) and triple-negative (TNBC; n= 84;
11.7 years of follow up] breast tumors (Supplementary
Tables S3 and S4). MASTL levels also correlated with Ki67
expression (as scored by immunohistochemistry) both in
hormone-positive tumors (Pearson’s R2= 0.28; p= 0.029;
(Fig. 6g) and TNBCs (Spearman’s rho= 0.396; p= 0.0003;
Supplementary Fig. S5). Clinical data conﬁrmed that
MASTL overexpression correlated with poor disease out-
come in hormone-positive tumors. Patients with high
MASTL levels had a median time to relapse of 4.06 years vs.
not reached for the remainder (average time: 5.5 vs. 10.8
years; HR= 3.4; 95% CI, 1.4–44.6; p= 0.02; Fig. 6h). The
low magnitude of the correlations observed between MASTL
and Ki67 suggests that MASTL might have an independent
impact in the disease prognosis regardless of its potential
functional implication in driving higher or lower replication
indexes. Interestingly, when adjusted by the conventional
prognostic factors, including high vs. low Ki67 using 14% as
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Fig. 4 Breast cancer cells require MASTL kinase activity. a Immuno-
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a cut-off point, high MASTL levels were highly and strongly
associated with poor clinical outcome, conferring a>3.5-fold
increase in the risk of relapse (Fig. 6i), suggesting a prog-
nostic role independent of the Ki67 fraction. A similar trend
was found in the TNBC cohort, although it did not reach
statistical signiﬁcance (Supplementary Fig. S5). These data
suggest that, besides its potential as a new druggable ther-
apeutic target, MASTL may also have a signiﬁcant prog-
nostic value in breast cancer.
Discussion
During recent years, MASTL has attracted signiﬁcant interest
as a kinase module that can inhibit major cellular phospha-
tases during mitosis. [7] The ability of MASTL to phos-
phorylate and activate small PP2A inhibitors has opened a
new paradigm in the direct control of phosphatases, and in
particular PP2A-B55 complexes, by kinases during cell cycle
progression [10, 11]. PP2A is a major tumor suppressor
whose activity is inhibited by different means in human
cancer. In addition to mutations in the scaffold subunits, B55α
(encoded by the PPP2R2A gene) and B55β (encoded by
PPP2R2B) subunits are occasionally eliminated by deletion or
hypermethylation of the corresponding genes [1, 3, 5] sug-
gesting the relevance of PP2A-B55 activity in preventing
breast cancer development. We therefore hypothesized that
MASTL activity could also contribute to breast cancer pro-
gression through the inactivation of these complexes.
Elimination of MASTL by RNA interference or CRISPR/
Cas9 technology prevents proliferation of certain luminal-
and basal-like breast tumor cell lines without a clear corre-
lation with speciﬁc histological subtypes. Previous work
suggested that exogenous overexpression of MASTL may
further trigger AKT activation in an ENSA/PP2A indepen-
dent manner [17]. However, we did not ﬁnd any correlation
between the protein levels of MASTL and the extent of AKT
phosphorylation in the panel of breast cell lines used in this
study. Importantly, our data indicates that downregulation of
endogenous MASTL in these cells, either using RNA
interference or CRISPR/Cas9 means, results in mitotic
defects accompanied by reduced phosphorylation of ENSA
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and CDK substrates. In line with these observations, these
defects can be rescued upon downregulation of B55 subunits
suggesting that the therapeutic effect of targeting MASTL is
at least partially due to its ability to inhibit PP2A-B55
complexes and that tumor cells with inactivation of B55 are
likely resistant to this therapeutic effect. None of the pro-
liferation defects caused by MASTL depletion could be
rescued by a kinase-deﬁcient mutant, demonstrating the
requirement of MASTL catalytic activity for proliferation of
breast tumor cells. Since MASTL is a druggable target, this
is especially relevant for the development of small-molecule
inhibitors and their potential therapeutic use in the future.
Besides the presence of its target B55, it remains to be
determined what the other requirements for sensitivity to
MASTL depletion are. A signiﬁcant number of breast tumor
cell lines were resistant to MASTL depletion despite
expressing normal levels of their targets, ENSA and B55,
suggesting unknown mechanisms of resistance.
In vivo, overexpression of MASTL contributes to the
growth of certain tumor cell lines in xenograft assays,
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whereas cells with MASTL knockdown display reduced
growth in these assays [17]. Yet, the therapeutic effect of
MASTL depletion in established tumors was not previously
tested. Using a new inducible CRISPR/Cas9 model in vivo
we have shown that ablation of MASTL in tumors results in
impaired tumor progression (Fig. 5). The results from this
assay likely underestimate the effect of MASTL ablation
since a signiﬁcant percentage of tumor cells maintain
MASTL expression as a technical limitation of this genetic
model. Yet, these results suggest that MASTL inhibition
may contribute to the reactivation of PP2A in speciﬁc tumor
types, an attractive possibility given the relevance of PP2A
activation as a therapeutic strategy in cancer [26].
Besides the relevance of MASTL as a potential new
therapeutic target for breast cancer, our data suggest it may
also have prognostic value in breast tumors. Overexpression
of MASTL at the protein level has been reported in several
tumor types [17–19], yet its correlation with disease outcome
was not deeply explored. Our data on breast cancer patients
indicates that high levels of MASTL protein correlates with
tumor aggressiveness and predicts poor survival in two
independent cohorts of ER+ tumors, in line with the con-
clusions from a recent report using mRNA data [27]. In
hormone-positive breast cancer, Ki67 is currently the most
important prognostic factor when adjusted by tumor size,
nodal status, or grade [28]. However this association is
usually evident in large patient series because the atributtable
risk to a high Ki67 fraction is relatively low. A multivariate
analysis, including high vs. low Ki67, showed that high
levels of MASTL constitute a Ki67-independent risk factor
for relapse in hormone-positive tumors. Interestingly, we also
found a strong association between MASTL overexpression
and poor prognosis in ER- tumors, a subtype where Ki67 did
not work as a prognostic factor. However, this association
was not detected at the mRNA level (Supplementary Fig. S4
and Ref. [27], perhaps reﬂecting either different mechanisms
of regulation of MASTL expression at the mRNA vs. protein
level in ER- tumors compared to ER+ ones, or heterogeneity
between the different patient cohorts used for mRNA versus
protein studies. Although new studies are required to
understand resistance mechanisms or possible synergies with
other therapeutic strategies, MASTL kinase emerges not only
as a new therapeutic target, but also as a potential biomarker
with prognostic value in breast cancer.
Materials and methods
Cell culture, drugs and cell proliferation analysis
All cancer cell lines were obtained from American Type
Culture Collection, and were maintained in DMEM or
RPMI-1640 medium supplemented with 10% fetal bovine
serum. The MDA-MB-231 cell line was authenticated by
short tandem repeat proﬁling, using the GenePrint 10 Sys-
tem (Promega). The identity of the other cells has not been
re-analyzed during the last 2 years. Mitotic cell extracts
were obtained by treating cells with nocodazole (0.8 µM)
during 14–16 h, and collecting cells by mitotic shake-off.
For cell proliferation assays, cells were seeded in 12-well
plates at low conﬂuence (1-2× 103 cells) and ﬁxed
10–15 days later with methanol. Colonies were stained with
crystal violet (0.1% wt/vol), washed extensively, and
imaged with a ﬂatbed scanner. Quantiﬁcation was per-
formed by using a colony Area Image J Plugin [29].
RNA interference and genetic editing by CRISPR/
Cas9 systems
Silencing of MASTL was performed using pLKO.1 lenti-
viral plasmids encoding speciﬁc shRNA sequences and
purchased from Sigma (Supplementary Table S1). To knock
down PPP2R2A and PPP2R2D transcripts, speciﬁc siRNAs
were purchased from Qiagen and transfected using Hiper-
fect (Qiagen), according to manufacturer’s instructions.
Genome editing of MASTL was performed with the
CRISPR/Cas9 system. PX459 and lentiCRISPRv2.0 back-
bone vectors were obtained from Addgene (plasmids 48139
and 52961, respectively). LC-TRIP (U6-sgRNA-TRE-
Cas9-P2A-dsRED-EFSGFP/Puro) lentiviral vector was
constructed based on the lentiCRISPR backbone [30].
Using standard cloning techniques, the P2A-Puro was
replaced by a P2A-dsRED with a 3′ multicloning site and
inserted stepwise the EFS promoter and a GFP-Puro fused
cassette downstream of the dsRED marker. In a last step,
the EFS promoter driving the expression of hCas9 was
replaced by the TRE promoter. All fragments were PCR-
ampliﬁed from TRMPVIR vector [31]. sgRNAs targeting
MASTL were designed according to available algorithms
(http://crispr.mit.edu/) and subcloned into the pX459, len-
tiCRISPRv2 and pLC-TRIP vectors. Indel mutations were
assessed by the T7E1 assay [32]. To generate iCas9 and
isgMASTL inducible cell lines, MDA-MB-231 cells were
infected with an rtTA-expressing retrovirus and selected
with puromycin (1 µg/ml). MDA-MB231-rtTA cells were
then infected with lentiviral LC-TRIP plasmids encoding
speciﬁc sgRNAs against MASTL, sorted for GFP-positive
cells and plated for single cell cloning. The expression of
Cas9 was induced by adding 2 µg/ml doxycycline to the
culture medium for 4 days. To exclude potential off-target
effects of sgMASTL, we identiﬁed top-ranking off-target
genomic sites (Supplementary Table S2) in the human
genome, using a published prediction tool [33].
For rescue assays, the Mastl kinase-dead mutant (G43S)
was generated by site-directed mutagenesis using mouse
Mastl cDNA as a template. Both wild-type and the G43S
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mutant were subcloned as GFP fusions into the pLVXpuro
lentiviral vector (Clontech).
Antibodies and immunodetection
Mouse monoclonal antibody to human MASTL (available
from Abcam, Riply 74C) was generated against recombi-
nant full-length protein corresponding to amino acids 1-879
of human MASTL fused to a GST tag. A speciﬁc rabbit
polyclonal antibody against the B55α PP2A subunit was
generated by immunization with a synthetic peptide com-
mon to the human and mouse sequence (MAGAGGGN-
DIQWCFS, Genscript).
For histological analysis tissues were ﬁxed in 10%-
buffered formalin (Sigma) and embedded in parafﬁn wax.
Sections of 3- or 5-μm thickness were stained with hae-
matoxylin and eosin. Additional immunohistochemical
examination was performed using speciﬁc antibodies
against Ki67 (Master Diagnostica), Cas9 (Cell Signaling)
and MASTL. The anti-MASTL antibody above described
was used for human samples, whereas anti-Mastl 4F9
(Millipore) antibody was used in mouse samples. For
immunoﬂuorescence, cells were plated on coverslips,
ﬁxed with 4% formaldehyde, permeabilized in 0.5%
Triton X-100, and stained with DAPI and an antibody
against α-tubulin (Sigma). For immunoblotting cells were
lysed in Laemmli buffer. Proteins were separated on TGX
Criterion Bis-Tris acrylamide gels (BioRad), transferred
to nitrocellulose membranes (BioRad), and probed using
the following speciﬁc antibodies: phospho-ENSA
(Ser67)/ARPP19 (Ser62), ENSA, phospho-p44/42
MAPK (Erk1/2) (Thr202/Tyr204), p44/42 MAPK (Erk1/
2), phospho-Akt (Thr308), phospho-Akt (Ser473), Akt,
and phospho-(Ser) CDKs Substrate from Cell Signaling;
β-actin and Flag from Sigma; GFP from Roche; phospho-
Histone H3 (Ser10) from Millipore; PP2A-B55-α (2G9)
from Santa Cruz Biotechnologies; PPP2R2D (N2C3)
from GeneTex; and MASTL and B55α antibodies gen-
erated in this study.
Flow-cytometry
Flow cytometry analysis of DNA content was performed by
cell ﬁxation with cold 70% Ethanol followed by staining
with 10 µg/ml Propidium Iodide (Sigma) or 10 μg/ml
Hoechst 3342 (Molecular Probes, Thermoﬁsher). Data
acquisition was performed with a LSR Fortessa analyzer
(BD Biosciences).
Time-lapse microscopy
Cells were plated on eight-well glass-bottom dishes (Ibidi)
and imaged with a Deltavision RT imaging system
(Olympus IX70/71, Applied Precision) equipped with a
Plan Apochromatic 20X/1.42 N.A. objective lens, and
maintained at 37 °C in a humidiﬁed CO2 chamber. Images
were acquired every 10 min, and analysis was performed
using ImageJ software.
Tumor mouse models
For xenograft tumor assays, athymic nude mice (7-week-
old females provided by Harlan Laboratories/ENVIGO),
were injected subcutaneously in both ﬂanks with 7× 106
cells corresponding to the indicated MDA-MB-231 indu-
cible clones (iCas9 or isgMASTL). Two weeks after injec-
tion, when tumors reached 100 mm3, mice were fed with
doxycycline-supplemented diet (2000 mg/Kg, Research
Diets Inc.). For each clone, 18 mice were divided in 3
experimental groups (6 mice/group): one group was
maintained with standard diet, a second group was fed with
doxycycline-supplemented diet during 2 weeks, and a third
group was also treated with doxycycline but only during
one week and then was switched back to standard diet
(transient induction). Tumors volumes were monitored
using caliper measurements. Mouse studies described in
this manuscript have been approved by the Institutional
Animal Care and Use Committee of the FIS-Comunidad de
Madrid.
Analysis of human tumors
Breast tumor samples from the METABRIC (Molecular
Taxonomy of Breast Cancer International Consortium)
study have been previously described. [3] Tumor samples
from the hormone-positive and triple negative breast cancer
cohorts were examined for tumor content by an expert
pathologist, and two 3-mm cores were selected from
cellular-rich regions, captured and randomly spotted into a
tissue microarray. The study protocol was reviewed and
approved by the Institutional Review Board at the Hospital
12 de Octubre (approval number 11/137).
An H-score (from 0 to 300) was generated for MASTL
staining by multiplying the percentage of MASTL positive
cells by the intensity score (0–3). The cut-off for high
MASTL expression was established in the mean value plus
one standard deviation, when the H-score showed a normal
distribution. In the cohorts where the H-score showed a
non-Gaussian distribution, the cut-off was established in
the upper quartile. Kaplan Meier estimates and log-rank
tests were used for studying the univariate impact of
MASTL staining. Cox regression was used to determine
the adjusted prognostic impact in disease relapse of
MASTL levels, adjusting by the conventional prognostic
variables.
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Statistical analysis
Statistical analysis was carried out using Prism 6 (Graphpad
Software Inc.). All statistical tests of comparative data were
done using two-sided, unpaired Student’s t-tests or ANOVA
for differential comparison between two groups or more
groups, respectively. In case of non-Gaussian distributions,
Mann-Whitney and Kruskal-Wallis tests were used for
comparison between two or more groups, respectively.
Correlation analysis was performed using Pearson’s test or,
alternatively, Spearman’s test for non-normal distributions.
Data with p< 0.05 were considered statistically signiﬁcant
(*, p< 0.05; **, p< 0.01; ***, p< 0.001; ****, p<
0.0001).
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